Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) profit net of tax attributable to owners of the parent was up 8% year over year to 146.1 million yuan in the third quarter of the year from 135.7 million yuan, according to a filing with the Singapore Exchange on Wednesday.
Earnings per share came in at 0.19 yuan compared with 0.17 yuan in the year-ago period.
Revenue was down 3% year over year to 1.65 billion yuan from 1.70 billion yuan, mainly due to a decrease in commercial sales.
Shares of the pharmaceutical company were down nearly 2% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments